vs
Side-by-side financial comparison of SCYNEXIS INC (SCYX) and Village Farms International, Inc. (VFF). Click either name above to swap in a different company.
SCYNEXIS INC is the larger business by last-quarter revenue ($18.6M vs $12.2M, roughly 1.5× Village Farms International, Inc.). SCYNEXIS INC runs the higher net margin — 65.7% vs 19.9%, a 45.9% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 31.5%).
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
Grafton Village Cheese Company is a cheesemaker in the town of Grafton in the U.S. state of Vermont. The company produces hand-crafted aged cheddar cheese.
SCYX vs VFF — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.6M | $12.2M |
| Net Profit | $12.3M | $2.4M |
| Gross Margin | — | — |
| Operating Margin | 56.3% | — |
| Net Margin | 65.7% | 19.9% |
| Revenue YoY | 1808.5% | 31.5% |
| Net Profit YoY | 376.5% | 128.2% |
| EPS (diluted) | $0.25 | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $18.6M | $12.2M | ||
| Q3 25 | $334.0K | $66.7M | ||
| Q2 25 | $1.4M | $59.9M | ||
| Q1 25 | $257.0K | $77.1M | ||
| Q4 24 | $977.0K | — | ||
| Q3 24 | $660.0K | $54.9M | ||
| Q2 24 | $736.0K | $53.6M | ||
| Q1 24 | $1.4M | $78.1M |
| Q4 25 | $12.3M | $2.4M | ||
| Q3 25 | $-8.6M | $10.2M | ||
| Q2 25 | $-6.9M | $26.5M | ||
| Q1 25 | $-5.4M | $-6.7M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-2.8M | $-820.0K | ||
| Q2 24 | $-14.5M | $-23.5M | ||
| Q1 24 | $411.0K | $-2.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | 47.9% | ||
| Q2 25 | — | 37.3% | ||
| Q1 25 | — | 14.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 24.8% | ||
| Q2 24 | — | 25.4% | ||
| Q1 24 | — | 19.9% |
| Q4 25 | 56.3% | — | ||
| Q3 25 | -2516.5% | 23.3% | ||
| Q2 25 | -701.0% | 20.8% | ||
| Q1 25 | -3350.2% | -8.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | -1563.6% | 3.8% | ||
| Q2 24 | -1255.0% | -43.5% | ||
| Q1 24 | -692.5% | -3.0% |
| Q4 25 | 65.7% | 19.9% | ||
| Q3 25 | -2572.2% | 15.3% | ||
| Q2 25 | -504.8% | 44.2% | ||
| Q1 25 | -2097.7% | -8.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | -425.5% | -1.5% | ||
| Q2 24 | -1964.4% | -43.9% | ||
| Q1 24 | 29.9% | -3.7% |
| Q4 25 | $0.25 | $0.01 | ||
| Q3 25 | $-0.17 | $0.08 | ||
| Q2 25 | $-0.14 | $0.24 | ||
| Q1 25 | $-0.11 | $-0.06 | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.06 | $-0.01 | ||
| Q2 24 | $-0.30 | $-0.21 | ||
| Q1 24 | $0.01 | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $40.0M | $81.2M |
| Total DebtLower is stronger | — | $33.7M |
| Stockholders' EquityBook value | $49.4M | $299.9M |
| Total Assets | $59.0M | $423.1M |
| Debt / EquityLower = less leverage | — | 0.11× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $40.0M | $81.2M | ||
| Q3 25 | $37.9M | $82.6M | ||
| Q2 25 | $44.8M | $60.0M | ||
| Q1 25 | $40.6M | $15.1M | ||
| Q4 24 | $59.3M | — | ||
| Q3 24 | $68.8M | $28.7M | ||
| Q2 24 | $73.0M | $29.7M | ||
| Q1 24 | $80.2M | $26.7M |
| Q4 25 | — | $33.7M | ||
| Q3 25 | — | $34.6M | ||
| Q2 25 | — | $39.1M | ||
| Q1 25 | — | $39.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $43.3M | ||
| Q2 24 | — | $44.4M | ||
| Q1 24 | — | $46.1M |
| Q4 25 | $49.4M | $299.9M | ||
| Q3 25 | $36.4M | $295.4M | ||
| Q2 25 | $44.5M | $284.3M | ||
| Q1 25 | $50.5M | $248.3M | ||
| Q4 24 | $55.1M | — | ||
| Q3 24 | $58.5M | $274.4M | ||
| Q2 24 | $60.4M | $275.2M | ||
| Q1 24 | $74.1M | $296.2M |
| Q4 25 | $59.0M | $423.1M | ||
| Q3 25 | $51.1M | $418.4M | ||
| Q2 25 | $60.7M | $403.7M | ||
| Q1 25 | $67.9M | $377.1M | ||
| Q4 24 | $90.6M | — | ||
| Q3 24 | $99.0M | $417.8M | ||
| Q2 24 | $107.8M | $425.4M | ||
| Q1 24 | $118.3M | $458.4M |
| Q4 25 | — | 0.11× | ||
| Q3 25 | — | 0.12× | ||
| Q2 25 | — | 0.14× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.16× | ||
| Q2 24 | — | 0.16× | ||
| Q1 24 | — | 0.16× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $18.4M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 90.8% |
| Cash ConversionOCF / Net Profit | 1.50× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.4M | — | ||
| Q3 25 | $-8.7M | $24.4M | ||
| Q2 25 | $-7.5M | — | ||
| Q1 25 | $-7.5M | $-6.4M | ||
| Q4 24 | $-24.0M | — | ||
| Q3 24 | $765.0K | $4.3M | ||
| Q2 24 | $-10.9M | $5.7M | ||
| Q1 24 | $-4.0M | $-50.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | $22.6M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-8.9M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $1.5M | ||
| Q2 24 | — | $4.8M | ||
| Q1 24 | — | $-1.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | 33.9% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -11.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.7% | ||
| Q2 24 | — | 9.0% | ||
| Q1 24 | — | -2.5% |
| Q4 25 | — | 90.8% | ||
| Q3 25 | — | 2.7% | ||
| Q2 25 | — | 4.6% | ||
| Q1 25 | — | 3.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 5.1% | ||
| Q2 24 | — | 1.6% | ||
| Q1 24 | — | 2.4% |
| Q4 25 | 1.50× | — | ||
| Q3 25 | — | 2.39× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -9.75× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
VFF
| International Sales | $8.7M | 71% |
| Cannabis United States Segment | $3.4M | 27% |
